EMERGING ACTIVITY OF CELLULAR IMMUNOTHERAPY FOR TREATMENT OF CANCER IN BRAZIL
REPORT FROM THE BRAZILIAN REGISTRY
DOI:
https://doi.org/10.46765/2675-374X.2024v5n2p235Abstract
Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved for standard of care treatment of patients with lymphoma and leukemia worldwide. Here we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and Center for International Blood and Marrow Transplant Research (CIBMTR). A total of 38 patients who received CAR T cells between 2020 and 2023. The median age was 47 years (range 4-77). Indications include Non-Hodgkin Lymphoma (NHL; 26 cases; 68%), Acute Lymphoblastic Leukemia (ALL; 9 cases; 24%), and Multiple Myeloma (MM; 3 cases; 8%). 84% (75% - 24 NHL cases and 25% - 8 ALL cases) were commercial. This report demonstrates the initial implementation of CAR T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Cinthya Corrêa da Silva, Anderson João Simione, Paula Moreira da Silva Sabaini, Antonio Vaz Macedo, Heliz Regina Alves das Neves, Monique Ammi , Flavia Ferreira da Costa, Valeria Viana, Adriana Mendes de Quadros Cavilha, Rosana Rocha Concilio, Phillip Scheinberg, Nelson Hamerschlak, Marco Aurelio Salvino, Adriana Seber , Yana Augusta Sarkis Novis, Vanderson Geraldo Rocha, Joaquim Gasparini dos Santos, Lucia Mariano da Rocha Silla, Ricardo Chiattone, Andreza Alice Feitosa Ribeiro, Vaneuza Araújo Moreira Funke, Leonardo Javier Arcuri, Lucila Nassif kerbauy, Jayr Schmidt Filho, Carmem Maria Sales Bonfim, Simone Ojima Ferreira, Marcelo Pasquini, Fernando Barroso Duarte
This work is licensed under a Creative Commons Attribution 4.0 International License.
